Non-alcoholic fatty liver disease: an emerging liver disease in Taiwan (Q26824416)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23089687%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

title

Non-alcoholic fatty liver disease: an emerging liver disease in Taiwan (English)

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23089687%20AND%20SRC:MED&resulttype=core&format=json

metabolic dysfunction–associated steatotic liver disease

16 February 2020

main subject

1 reference

non-alcoholic fatty liver

inferred from title

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23089687%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

Ching-Sheng Hsu

series ordinal

1

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23089687%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

language of work or name

1 reference

11 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23089687%20AND%20SRC:MED&resulttype=core&format=json

Journal of the Formosan Medical Association

16 February 2020

published in

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23089687%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

volume

111

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23089687%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

10

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23089687%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

527-535

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23089687%20AND%20SRC:MED&resulttype=core&format=json

Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway

16 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Nonalcoholic fatty liver disease: from steatosis to cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Adipokines in liver diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Hepatic steatosis: innocent bystander or guilty party?

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Thioacetamide induced liver damage in zebrafish embryo as a disease model for steatohepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Correlations of laparoscopy with histology and laboratory studies on liver diseases in bariatric patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Metabolic syndrome is related to nonalcoholic steatohepatitis in severely obese subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Metabolic profiles in patients with chronic hepatitis C: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Overexpression of gankyrin induces liver steatosis in zebrafish (Danio rerio).

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Fatty acid composition and lipid peroxidation of soft-shelled turtle, Pelodiscus sinensis, fed different dietary lipid sources

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Epidemiology and natural history of non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Metformin regulates hepatic lipid metabolism through activating AMP-activated protein kinase and inducing ATGL in laying hens

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

A position statement on NAFLD/NASH based on the EASL 2009 special conference

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Epidemic obesity and type 2 diabetes in Asia

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

MCT/LCT emulsion ameliorate liver fat deposition in insulin-treated diabetic rats receiving total parenteral nutrition

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Disease Progression in a Patient with Nonalcoholic Steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic Fatty liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Effects of therapeutic lifestyle program on ultrasound-diagnosed nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Metabolic syndrome as a risk factor for nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock?

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Fatty liver and the metabolic syndrome among Shanghai adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Significant correlations between severe fatty liver and risk factors for metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

How should we manage patients with non-alcoholic fatty liver disease in 2007?

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences?

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Human fatty liver disease: old questions and new insights

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Future use of the Glasgow alcoholic hepatitis score

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Pioglitazone retrieves hepatic antioxidant DNA repair in a mice model of high fat diet

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Clinical correlation of nonalcoholic fatty liver disease in a Chinese taxi drivers population in Taiwan: Experience at a teaching hospital

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Obesity and Liver Disease: Evaluation of Fatty Infiltration of the Liver Using Ultrasonic Attenuation

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Prevalence of HFE mutations and relation to serum iron status in patients with chronic hepatitis C and patients with nonalcoholic fatty liver disease in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JFMA.2012.07.002

7 January 2021

10.1016/J.JFMA.2012.07.002

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23089687%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

Consolidated OpenCitations Corpus – April 2017

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23089687%20AND%20SRC:MED&resulttype=core&format=json